Checkpoint Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2018

Stockholders' Equity Note [Abstract]

Nonvested Restricted Stock Shares Activity [Table Text Block]

The following table summarizes restricted stock award activity for the year ended December 31, 2018 and 2017:

	Number of Units			Weighted Average Grant Date Fair Value
Nonvested at December 31, 2016		2,533,063		$	2.93
Granted		359,303			7.69
Vested		(281,250	)		0.07
Nonvested at December 31, 2017		2,611,116		$	3.89
Granted		616,240			3.75
Vested		(295,250	)		0.29
Nonvested at December 31, 2018		2,932,106		$	4.22

Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes stock option award activity for the year ended December 31, 2018 and 2017.

	Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2016		60,000	$	5.43		9.96
Granted		-		-
Outstanding as of December 31, 2017		60,000	$	5.43		9.09
Granted		-		-
Outstanding as of December 31, 2018		60,000	$	5.43		8.09

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

A summary of warrant activities for year ended December 31, 2018 and 2017 is presented below:

	Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2016		4,331,106		$	6.62		4.67
Granted		-			-
Exercised		(4,551	)		-
Outstanding as of December 31, 2017		4,326,555		$	6.62		3.67
Granted		-			-
Exercised		(45,583	)		-
Outstanding as of December 31, 2018		4,280,972		$	6.69		2.33

Share-based Compensation, Activity [Table Text Block]

The following table summarizes stock-based compensation expense for the years ended December 31, 2018 and 2017 ($ in thousands).

	For the year ended December 31,
	2018		2017
Research and development	$	95	$	1,180
General and administrative		1,899		1,937
Total stock-based compensation expense	$	1,994	$	3,117

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details